In late-breaking phase 3 results, pozdeutinurad lowered serum urate through 12 months in patients with uncontrolled gout
Pozdeutinurad lowered serum urate below 6 mg/dL at month 6 in more patients with uncontrolled gout than placebo, with reductions ...
